What is the best practice for HPV testing in male patients, including recommendations for asymptomatic men and high‑risk groups such as men who have sex with men, HIV‑positive, and immunocompromised individuals?

HPV Testing in Male Patients: Evidence-Based Recommendations

Primary Recommendation for Asymptomatic Men

Routine HPV testing is not recommended for asymptomatic men in the general population because no FDA-approved or clinically validated HPV test exists for males, and most HPV infections in men clear spontaneously without causing disease. 1

Why Testing Is Not Performed

• No validated diagnostic test: All FDA-cleared HPV assays are designed exclusively for cervical specimens and have not been validated for penile, anal, or oral samples in men 1
• Transient natural history: The majority of HPV infections in men resolve within one year without intervention, making screening of limited clinical utility 2
• Lack of treatment: No antiviral agents exist to eradicate HPV infection itself; only HPV-associated lesions (such as genital warts) can be treated 3

Clinical Approach for Asymptomatic Men

Instead of laboratory testing, focus on:

• Visual examination: Diagnose genital warts—the most common HPV manifestation in men—through clinical inspection rather than molecular testing 1
• Vaccination: Strongly recommend HPV vaccination for all males aged 9-21 years, with catch-up vaccination for males aged 22-26 years who were not previously vaccinated 1, 4
• Partner counseling: Reassure patients that HPV detection in a female partner does not indicate infidelity, as infection can persist asymptomatically for years and most sexually active adults acquire HPV at some point 1

---

High-Risk Populations Requiring Specialized Screening

Men Who Have Sex with Men (MSM)

Annual anal cytology (anal Pap test) should be considered for MSM, particularly those who are HIV-positive, but only in clinical settings where high-resolution anoscopy (HRA) is available for follow-up of abnormal results. 1, 4

• Anal cancer incidence in HIV-positive MSM is dramatically elevated at 80-131 cases per 100,000 person-years, compared to 1-2 cases per 100,000 in the general population 3
• HIV-negative MSM with receptive anal intercourse history also have elevated risk at 14 cases per 100,000 person-years 3
• Digital anorectal examination (DARE) should be performed annually to detect palpable masses in MSM with a history of receptive anal intercourse 3

HIV-Positive Men

All HIV-infected men should receive annual anal cytology screening regardless of sexual practices, with any abnormal results requiring HRA with biopsy. 4

• HIV-infected men have anal cancer incidence of 40-60 cases per 100,000 person-years 3
• HIV-infected individuals with genital warts require particularly close surveillance with anal cytology 4
• Critical caveat: Anal cytology screening should only be performed where HRA expertise is available, as abnormal cytology without appropriate follow-up capability provides no clinical benefit 1

Immunocompromised Patients

• Men on chronic immunosuppressive therapy (organ transplant recipients, chronic corticosteroid use) should be managed similarly to HIV-positive patients with consideration for anal cytology screening 3
• Immunosuppression increases risk of persistent HPV infection and progression to dysplasia 3

---

Vaccination Strategy (Prevention Over Detection)

HPV vaccination represents the most effective intervention for male patients and should be prioritized over any screening strategy. 1

Age-Based Recommendations

• Ages 9-21 years: Routine vaccination strongly recommended for all males (ideally initiated at ages 11-12 years) 3, 1
• Ages 22-26 years: Vaccination recommended if not previously vaccinated 1
• HIV-infected males: Three-dose series recommended regardless of age within the 9-26 year range 1, 4
• MSM: Vaccination through age 26 years if not previously vaccinated 3

Vaccine Selection

• Quadrivalent (4vHPV) or 9-valent (9vHPV) vaccines are recommended for males 3
• The vaccine prevents infection with HPV types causing approximately 70% of anal cancers and 90% of genital warts 1

---

Risk Reduction Counseling

Transmission Prevention

• Condom use: Consistent condom use may reduce transmission risk, though HPV can infect skin areas not covered by condoms 1, 2
• Partner notification: When HPV-related disease is detected, screen both partners for other sexually transmitted infections 3

Patient Education Points

• Most HPV infections are asymptomatic; absence of symptoms does not mean absence of infection 2
• Different HPV types have different oncogenic potential—types causing genital warts (types 6,11) differ from those causing cancers (types 16,18) 2
• HPV can be transmitted even when no visible signs or symptoms are present 2
• Clearance of detectable virus does not guarantee complete elimination, as latent infection may persist 2

---

Common Pitfalls to Avoid

• Do not order urine HPV testing: Urine samples have poor sensitivity for HPV detection in men, particularly in asymptomatic low-risk populations, and are not clinically validated 5
• Do not perform anal cytology without HRA access: Screening without the ability to perform diagnostic HRA and treatment creates clinical dead-ends and patient anxiety without benefit 1
• Do not withhold vaccination based on presumed prior exposure: Even sexually active individuals may benefit from vaccination against HPV types to which they have not yet been exposed 3
• Do not screen partners of women with cervical dysplasia: Male partners of women with HPV-related cervical lesions do not require routine testing, as no validated test exists and management would not change 1